Search filters

List of works by Shahneen K Sandhu

A community-based model of rapid autopsy in end-stage cancer patients

scientific article published on 12 September 2016

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

scientific article

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

scientific article published in October 2014

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

scientific article published on 26 September 2019

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

scientific article published on 29 September 2016

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.

scientific article published on 8 August 2013

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

scientific article

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

scientific article published on 29 April 2011

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

scientific article published on 29 July 2020

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series

scientific article published on 01 February 2019

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

scientific article published on 01 May 2011

Cell cycle control as a promising target in melanoma

scientific article

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target

scientific article published on 20 March 2019

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

scientific article published on 27 April 2017

Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy

scientific article published on 16 October 2020

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

scientific article published on 29 January 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

scientific article published on 27 March 2018

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer ⬇️

scientific article

Diabetes associated with immune checkpoint inhibition: presentation and management challenges

scientific article published on 16 June 2018

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

scientific article published on 22 November 2016

Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and "whole body" tumor dosimetry with treatment outcomes

scientific article published on 05 October 2018

E6AP promotes prostate cancer by reducing p27 expression

scientific article published on 19 April 2017

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis

scientific article published on 12 July 2019

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

scientific article published on 06 August 2013

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer

scientific article published on 18 June 2019

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

scientific article published on 27 July 2017

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel

scientific article published on 05 February 2019

HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.

scientific article published on December 2011

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

scientific article published on 20 August 2014

Identification of single nucleotide variants using position-specific error estimation in deep sequencing data

scientific article published on 02 August 2019

Integration of Immuno-Oncology and Palliative Care

scientific article published on 29 February 2016

Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors

scientific article published on 22 April 2020

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

scientific article published on 31 August 2020

Microbiome transplantation and modulation of immune related adverse events

scientific article published on 01 February 2019

Mortality due to immunotherapy related hepatitis

scientific article published on 06 August 2018

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

scientific article published on 24 July 2018

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy

scientific article published on 23 July 2018

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

scientific article

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

scientific article published on 05 August 2019

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.

scientific article

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

scientific article published on 17 February 2014

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

scientific article published on 22 March 2013

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic ⬇️

scientific article published on 04 January 2011

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

scientific article published on January 2010

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

scientific article published on 13 December 2018

Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection.

scientific article published on 11 January 2017

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

scientific article published on 01 May 2019

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

scientific article published on 09 October 2012

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics

scientific article published on 05 January 2019

Prostate-specific membrane antigen theranostics: therapy with lutetium-177.

scientific article

RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer ⬇️

scientific article published on September 24, 2010

Recent Insights and Advances in the Management of Merkel Cell Carcinoma.

scientific article

Relevance of DNA damage repair in the management of prostate cancer

scientific article

Reply to M. Horiguchi et al.

scientific article

Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.

scientific article published on 3 December 2013

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

scientific article published on 13 November 2018

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

scientific article

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

scientific article published on 19 October 2017

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

article by Louise J Barber et al published 25 January 2013 in Journal of Pathology

Sentinel node biopsy for melanoma: The medical oncology perspective

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

scientific article published on 01 July 2018

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

scientific article published on January 2015

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

scientific article published on 2 August 2016

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment ⬇️

scientific article published on December 1, 2011

The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.

scientific article published on 25 January 2017

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

scientific article

The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors

scientific article published on 04 June 2019

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

scientific article published on 09 February 2016

Toward a better dialogue between neuro-oncologists and phase I investigators.

scientific article

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer

scientific article published on 05 April 2011

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

scientific article published on 15 December 2015

Use of vemurafenib in a patient unable to swallow whole.

scientific article

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

scientific article

When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'.

scientific article

[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply

scientific article published on 01 August 2018

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

scientific article published on 08 May 2018

Paulina is supported by:

About Paulina

Help